Related Experiment Video

Updated: Aug 16, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Prostate cancer, biological therapy, signal transduction inhibitors and anti-angiogenesis agents

C McKinnon1

  • 1Current Drugs Ltd, Middlesex House, 34-42 Cleveland Street, London W1P 6LB, United Kingdom. colinm@cursci.co.uk

Idrugs : the Investigational Drugs Journal
|August 30, 2005
PubMed

Insights

New systemic treatments for prostate cancer, including biological therapies like vaccines and antibodies, alongside signal transduction inhibitors and anti-angiogenesis agents, were highlighted. These advancements offer novel therapeutic strategies for patients with advanced prostate cancer.

Area of Science:

  • Oncology
  • Medical Research

Background:

  • Prostate cancer remains a significant health concern, necessitating innovative treatment modalities.
  • Existing therapies face limitations, driving the search for more effective systemic approaches.

Purpose of the Study:

  • To review and highlight emerging systemic treatments for prostate cancer discussed at recent ASCO sessions.
  • To focus on novel biological therapies, signal transduction inhibitors, and anti-angiogenesis agents.

Main Methods:

  • Review of presentations and discussions from ASCO sessions focused on prostate cancer therapeutics.
  • Categorization of new systemic approaches into biological therapy, signal transduction inhibitors, and anti-angiogenesis agents.

Main Results:

  • Biological therapy, including vaccines and antibodies, presents a promising avenue for prostate cancer treatment.
  • Signal transduction inhibitors offer targeted mechanisms to disrupt cancer cell growth pathways.
  • Anti-angiogenesis agents aim to inhibit the formation of new blood vessels that supply tumors.

Conclusions:

  • The discussed systemic approaches represent significant advancements in prostate cancer management.
  • These novel therapies hold potential for improved patient outcomes and expanded treatment options.

More Related Videos

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

Mimicking the Function of Signaling Proteins: Toward Artificial Signal Transduction Therapy12:24

Mimicking the Function of Signaling Proteins: Toward Artificial Signal Transduction Therapy

Published on: September 29, 2016

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...